Original Papers

218. Pekayvaz K, Losert C, Knottenberg V, Gold C, van Blokland IV, Oelen R, Groot HE, Benjamins JW, Brambs S, Kaiser R, Gottschlich A, Hoffmann GV, Eivers L, Martinez-Navarro A, Bruns N, Stiller S, Akgöl S, Yue K, Polewka V, Escaig R, Joppich M, Janjic A, Popp O, Kobold S, Petzold T, Zimmer R, Enard W, Saar K, Mertins P, Huebner N, van der Harst P, Franke LH, van der Wijst MGP, Massberg S, Heinig M, Nicolai L, Stark K. 
Multiomic analyses uncover immunological signatures in acute and chronic coronary syndromes.
Nature Medicine 2024; 30:1696-1710.
JIF²⁰²² 87.2

https://pubmed.ncbi.nlm.nih.gov/38773340/

218. Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, Wälchli S. 
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
Cell Reports Medicine 2024; 5:101572.
JIF²⁰²² 11.7

https://pubmed.ncbi.nlm.nih.gov/38773340/

218. Lacher SB, Dörr J, de Almeida GP, Hönninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, Spranger N, Morotti M, Grimm AJ, Jarosch S, Oner A, Gregor L, Lesch S, Michaelides S, Fertig L, Briukhovetska D, Majed L, Stock S, Busch DH, Buchholz VR, Knolle PA, Zehn D, Dangaj Laniti D, Kobold S, Böttcher JP.
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Nature 2024; 629:417-425.
JIF²⁰²² 64.8

https://pubmed.ncbi.nlm.nih.gov/38658748/

218. Stock S, Fertig L, Gottschlich A, Dörr J, Märkl F, Majed L, Menkhoff VD, Grünmeier R, Rejeski K, Cordas Dos Santos DM, Theurich S, von Bergwelt-Baildon M, Endres S, Subklewe M, Kobold S.
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.  
Cancer Immunology Immunotherapy 2024; 73:100.
JIF²⁰²² 5.8

https://pubmed.ncbi.nlm.nih.gov/38630291/

217. Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S, Binder M. 
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.
Nature Communications 2024;15:993.
JIF²⁰²² 14.7

https://pubmed.ncbi.nlm.nih.gov/38307904/

217. Santos-Peral A, Luppa F, Goresch S, Nikolova E, Zaucha M, Lehmann L, Dahlstroem F, Karimzadeh H, Thorn-Seshold J, Winheim E, Schuster EM, Dobler G, Hoelscher M, Kümmerer BM, Endres S, Schober K, Krug AB, Pritsch M, Barba-Spaeth G, Rothenfusser S.
Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection.
Nature Communications 2024; 15:1696.
JIF²⁰²² 17.7

https://pubmed.ncbi.nlm.nih.gov/38402207/

216. Xhaxho S, Chen-Wichmann L, Kreissig S, Windisch R, Gottschlich A, Nandi S, Schabernack S, Kohler I, Kellner C, Kobold S, Humpe A, Wichmann C. 
Efficient chimeric antigen receptor t-cell generation starting with leukoreduction system chambers of thrombocyte apheresis sets.
Transfusion Medical Hemotherapy 2023 Aug 30;51(2):111-118. 

JIF²⁰²² 2.2

https://pubmed.ncbi.nlm.nih.gov/38584695/

216. Rasulova M, Vercruysse T, Paulissen J, Coun C, Suin V, Heyndrickx L, Ma J, Geerts K, Timmermans J, Mishra N, Li LH, Kum DB, Coelmont L, Van Gucht S, Karimzadeh H, Thorn-Seshold J, Rothenfusser S, Ariën KK, Neyts J, Dallmeier K, Thibaut HJ.
A high-throughput yellow fever neutralization assay.
Microbiology Spectrum 2022 10:e0254821.
JIF²⁰²² 4.4

https://pubmed.ncbi.nlm.nih.gov/35670599/

216. Winheim E, Eser T, Deák F, Ahmed MIM, Baranov O, Rinke L, Eisenächer K, Santos-Peral A, Karimzadeh H, Pritsch M, Scherer C, Muenchhoff M, Hellmuth JC, von Bergwelt-Baildon M, Olbrich L, Hoelscher M, Wieser A, Kroidl I, Rothenfusser S, Geldmacher C, Krug AB.
Distinct and dynamic activation profiles of circulating dendritic cells and monocytes in mild COVID-19 and after yellow fever vaccination.
European Journal of Immunology 2023; 53:e2250090.
JIF²⁰²² 4.4

https://pubmed.ncbi.nlm.nih.gov/36404054/

216. Fidelle M, ... , Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, ... , Derosa L, Kroemer G, Zitvogel L.
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.
Science 2023; 380:eabo2296.
JIF²⁰²² 56.9

https://pubmed.ncbi.nlm.nih.gov/37289890/

216. Heeb LV, Taskoparan B, Katsoulas A, Beffinger M, Clavien PA, Kobold S, Gupta A, Berg JV.
HDR-based CRISPR/Cas9-mediated knockout of PD-L1 in C57BL/6 mice.
Bio Protocol 2023; 20;13:e4724.
JIF²⁰²² 2.1

https://pubmed.ncbi.nlm.nih.gov/37497456/

216. McCarthy D, Lofgren M, Watt A, Horton H, Kieffer-Kwon P, Ding J, Kobold S, Baeuerle PA, Hofmeister R, Gutierrez DA, Tighe R.
Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor.
Cancer Immunology Immunotherapy 2023; 72:4195-4207.
JIF²⁰²² 5.8

https://pubmed.ncbi.nlm.nih.gov/37848682/

216. Wu H, Zhao X, Hochrein SM, Eckstein M, Gubert GF, Knöpper K, Mansilla AM, Öner A, Doucet-Ladevèze R, Schmitz W, Ghesquière B, Theurich S, Dudek J, Gasteiger G, Zernecke A, Kobold S, Kastenmüller W, Vaeth M.
Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming.
Nature Communications 2023; 14:6858.
JIF²⁰²² 17.7

https://pubmed.ncbi.nlm.nih.gov/37891230/

216. Nowotny HF, Marchant Seiter T, Ju J, Gottschlich A, Schneider H, Zopp S, Vogel F, Tschaidse L, Auer MK, Lottspeich C, Kobold S, Rothenfusser S, Beuschlein F, Reincke M, Braun L, Reisch N.
Major immunophenotypic abnormalities in patients with primary adrenal insufficiency of different etiology.
Frontiers in Immunology 2023; 14:1275828.
JIF²⁰²² 7.3

https://pubmed.ncbi.nlm.nih.gov/38045693/

216. Becker M, Joseph S, Garcia-Carrizo F, Tom R, Opaleva D, Serr I, Tschöp M, Schulz T, Hofmann S, Daniel C.
Regulatory T cells require IL6 receptor alpha signaling to control skeletal muscle function and regeneration.
Cell Metabolism 2023, 35:1736-1751.
JIF²⁰²² 29,0

https://authors.elsevier.com/sd/article/S1550-4131(23)00331-5

216. Lesch S, Nottebrock A, Rataj F, Heise C, Endres S, Kobold S.
PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models.
Cellular Oncology 2023; 46:227-235.
JIF²⁰²¹ 7.1

https://pubmed.ncbi.nlm.nih.gov/36409438/

215. Wagenbauer K, Pham N, Gottschlich A, Kick B, Kozina V, Frank Ch, Trninic D, Stömmer P, Grünmeier R, Carlini E, Tsiverioti Ch, Kobold S, Funke J, Dietz H.
Programmable multispecific DNA-origami-based T-cell engagers.
Nature Nanotechnology 2023, 18:1319-1326.
JIF²⁰²² 38,3

https://www.lmu.de/de/newsroom/newsuebersicht/news/immuntherapie-antikoerper-bausatz-gegen-tumore.html

215. Leonhardt A, Anz D, Kunz W, Röhrle N, Tomsitz D, French LE, Seegräber M, Heinzerling L.
Tumor lysis syndrome induced by Tebentafusp.
Immunotherapy 2023, 15:1363-1368.
JIF²⁰²² 2.8

https://pubmed.ncbi.nlm.nih.gov/37661909/

215. Thompson J, Wang Y, Dreischulte T, Barreiro O, Gonzalez RJ, Hanč P, Matysiak C, Neely HR, Rottenkolber M, Haskell T, Endres S, von Andrian U.
Association between bisphosphonate use and COVID-19-related outcomes.
e-life 2023, 3:12:e79548.
JIF²⁰²² 8.7

https://elifesciences.org/articles/79548
Knochenschwund-Medikamente gegen Corona? | LMU Klinikum (lmu-klinikum.de)

214. Lorenzini T, Cadilha B, Obeck H, Benmebarek MR, Märkl F, Michaelides S, Strzalkowski T, Briukhovetska D, Müller P, Nandi S, Winter P, Majed L, Grünmeier R, Seifert M, Rausch S, Feuchtinger T, Endres S, Kobold S.
Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy.
British Journal of Cancer 2023, 129:696-705.
JIF²⁰²² 9.0

https://pubmed.ncbi.nlm.nih.gov/37400680/

213. Märkl F, Benmebarek MR, Keyl J, Cadilha B, Geiger M, Karches C, Obeck H, Schwerdtfeger M, Michaelides S, Briukhovetska D, Stock S,  Jobst J, Müller P, Majed L, Seifert M, Klüver A, Lorenzini T, Grünmeier R, Thomas M, Gottschlich A, Klaus R, Marr C, von Bergwelt-Baildon M, Rothenfusser S, Levesque M, Heppt M, Endres S, Klein C, Kobold S.
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Journal for Immunotherapy of Cancer 2023, 11:e006436.
JIF²⁰²² 12.5

https://pubmed.ncbi.nlm.nih.gov/37208128/ 

212. Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti Ch, Carlini E, Nandi S, Strzalkowski T, Lorenzini  T, Stock S, Müller P, Dörr J, Seifert M, Cadilha B, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner Ch, Beltrán E, Herold T, Paquet D,  Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S.
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Nature Biotechnology 2023, 41:1618-1632.
JIF²⁰²² 68.2

https://pubmed.ncbi.nlm.nih.gov/36914885/

211. Wheeler MA, Clark I, Lee HG, Li Z, Linnerbauer M, Rone JM, Blain M, Akl CF , Piester G, Giovannoni F, Charabati M, Lee JH, Kye YC, Choi J, Sanmarco LM, Srun L, Chung EN, Flausino LE , Andersen BM, Rothhammer V, Yano H, Illouz T, Zandee SEJ, Daniel C, Artis D, Prinz M, Abate AR, Kuchroo VK, Antel JP, Prat A, Quintana FJ.
Droplet-based forward genetic screening of astrocyte-microglia cross-talk.
Science 2023; 379:1023-1030.
JIF²⁰²² 63.7

https://pubmed.ncbi.nlm.nih.gov/36893254/

211. Tao Xu T, Karschnia P, Cadilha B, Dede S, Lorenz M, Seewaldt N, Nikolaishvili E, Müller K, Blobner J, Teske J, Herold J, Rejeski K, Langer S, Obeck H, Lorenzini T, Mulazzani M, Zhang W, Ishikawa-Ankerhold H, Buchholz V, Subklewe M, Thon N, Straube A, Tonn JC, Kobold S, von Baumgarten L.
In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer.
OncoImmunology 2023; 12:2163781.
JIF²⁰²² 7.0

https://pubmed.ncbi.nlm.nih.gov/36687005/

211. Giannou A, Kempski J, Shiri AM, Leucke J, Zhang T, Zhao L, Zazara D, Cortesi F, Riecken K, Amezcua Vesely MA, Low JS, Xu H, Kaffe E, Garcia-Perez L, Agalioti T, Yamada Y, Jungraithmayr W, Zigmond E, Karstens KF, Steglich B, Wagner J, Konczalla L, Carambia A, Schulze K, von Felden J, May P, Briukhovetska D, ...Suarez-Gosalvez J, Kobold S, ...Huber S.
Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22.
Immunity 2023; 125–142.
JIF²⁰²² 43.5
https://authors.elsevier.com/sd/article/S1074761322006501

210. Rasulova M, Vercruysse T, Paulissen J, Coun C, Suin V, Heyndrickx L, Ma J, Geerts K, Timmermans J, Mishra N, Li LH, Kum DB, Coelmont L, Van Gucht S, Karimzadeh H, Thorn-Seshold J, Rothenfusser S, Ariën KK, Neyts J, Dallmeier K, Thibaut HJ.
A High-Throughput Yellow Fever Neutralization Assay.
Microbiology Spectrum 2022 10:e0254821.
JIF²⁰²² 9.0

https://pubmed.ncbi.nlm.nih.gov/35670599/

210. Scherm MG, Wyatt RC, Serr I, Anz D, Richardson SJ, Daniel C.
Beta cell and immune cell interactions in autoimmune type 1 diabetes: How they meet and talk to each other.
Molecular Metabolism 2022; 64:101565.
JIF²⁰²¹ 8.6

https://pubmed.ncbi.nlm.nih.gov/35944899/

210. Blaeschke F, Ortner E, Stenger D, Mahdawi J, Apfelbeck A, Habjan N, Weißer T, Kaeuferle T, Willier S, Kobold S, Feuchtinger T.
Design and evaluation of TIM-3-CD28 checkpoint fusion proteins to improve anti-CD19 CAR T-cell function
Frontiers in Immunology 2022; 13:845499.
JIF²⁰²¹ 8.8

https://pubmed.ncbi.nlm.nih.gov/35499080/

210. Demel U,  Böger M, Yousefian S, Grunert C, Zhang L, Hotz P, Gottschlich A, Köse H, Isaakidis K, Vonficht D, Grünschläger F, Rohleder E, Wagner K, Dönig J, Igl V, Brzezicha B, Baumgartner F, Habringer S, Löber J, Chapuy J, Weidinger C, Kobold S, Haas S, Busse A, Müller S, Wirth M, Schick M, Keller U.
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
The Journal of Clinical Investigation 2022; 132:e152383.

JIF²⁰²¹ 19.5

https://pubmed.ncbi.nlm.nih.gov/35499080/

210. Lesch S, Nottebrock A, Rataj F, Heise C, Endres S, Kobold S.
PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models.
Cellular Oncology 2022; 46:227-235.
JIF²⁰²¹ 7.1

https://pubmed.ncbi.nlm.nih.gov/36409438/

209. Summer B, Lill D, Remmel K, Schraml A, Schopf C, IBanke IJ, Kuechenhoff H, Maierhofer T, Endres S, Thomas P.
An interleukin-1 polymorphism additionally intensified by atopy as prognostic factor for aseptic non-mechanical complications in metal knee and hip arthroplasty.
Frontiers in Immunology 2022; 13:1050315.
JIF²⁰²¹ 8.8

https://pubmed.ncbi.nlm.nih.gov/36518750/

208. Seifert M, Benmebarek MR, Briukhovetska D, Märkl F, Dörr J, Cadilha B, Jobst J, Stock S, Andreu-Sanz D, Lorenzini T, Grünmeier R, Öner A, Obeck H, Majed L, Dhoqina D, Feinendegen M, Gottschlich A, Zhang J, Schindler U, Endres S, Kobold S.
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function.
British Journal of Cancer 2022; 61, eabe2550.
JIF²⁰²¹ 9.1

https://pubmed.ncbi.nlm.nih.gov/36266575/

207. Hölting TLB, Cidre-Aranaz F, Matzek D, Popper B, Jacobi SJ, Funk CM, Geyer FH, Li J, Piseddu I, Cadilha BL, Ledderose S, Zwilling J, Ohmura S, Anz D, Künkele A, Klauschen F, Grünewald TGP, Knott MML.
Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood
sarcoma.
Molecular Cancer 2022, 21:199.
JIF²⁰²¹ 41.4
https://pubmed.ncbi.nlm.nih.gov/36229873/

207. Stazzoni S, Böhmer D, Hernichel F, Özdemir D, Pappa A, Drexler D, Bauernfried S, Witte G, Wagner M, Veth S, Hopfner KP, Hornung V, König LM, Carell T.
Novel poxin stable cGAMP-derivatives are remarkable STING agonists.
Angewandte Chemie 2022; 10:e202207175.
JIF²⁰²¹ 15.3
https://pubmed.ncbi.nlm.nih.gov/35876840/

207. Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost Ch, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein Ch, Kobold S.
Chimeric antigen receptor T cells engineered to recogniz the P329G- mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Journal for Immunotherapy of Cancer 2022; 10:e005054.
JIF²⁰²¹ 12.5
https://jitc.bmj.com/content/10/7/e005054

206. Bashiri Dezfouli A, Yazdi M, Benmebarek MR, Schwab M, Michaelides S, Miccichè A, Geerts D, Stefan S, Klapproth S, Wagner E, Kobold S, Gabriele Multhoff G.
CAR T cells targeting membrane-bound Hsp70 on tumor cells mimic Hsp70-primed NK cells.
Frontiers in Immunology 2022; 13:883694.
JIF²⁰²¹ 8.8

https://pubmed.ncbi.nlm.nih.gov/35720311/

206. Lücke AC, vom Hemdt A, Wieseler J, Fischer C, Feldmann M, Rothenfusser S, Drexler JF, Kümmerer BM.
High-throughput platform for detection of neutralizing antibodies using flavivirus reporter replicon particles.
Viruses 2022; 4:346.
JIF²⁰²¹ 5.0

https://pubmed.ncbi.nlm.nih.gov/35215941/

206. Arendt K, Ntaliarda G, Armenis V, Kati D, Henning Ch, Giotopoulou G, Pepe M, Klotz L, Lamort A, Hatz R, Kobold S, Schamberger A, Stathopoulos G.
An in vivo inflammatory loop potentiates KRAS blockade.
Biomedicines 2022; 10,592.
JIF²⁰²¹ 6.1

https://pubmed.ncbi.nlm.nih.gov/35327394/

206. Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K, Forster M, Wessels U, Stubenrauch KG, Benz J, Ehler A, Lauer ME, Ringler P, Kobold S, Endres S, Klein Ch, Brinkmann U.
Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies.
Biological Chemistry 2022; 403:495-508.
JIF²⁰²¹ 5.2

https://pubmed.ncbi.nlm.nih.gov/35073465/

205. Scheck MK, Lehmann L, Zaucha M, Schwarzlmueller P, Huber K, Pritsch M, Barba-Spaeth G, Thorn-Seshold O, Krug AB, Endres S, Rothenfusser S, Thorn-Seshold J.
FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D.
PLOS One 2022; 17:e0262149.
JIF²⁰²¹ 3.8

https://pubmed.ncbi.nlm.nih.gov/35139078/

204. Darwich A, Silvestri A, Benmebarek MR, Mouries J, Melacarne A, Cadilha B, Taleb A, Supino D, Obeck H, Sustmann C, Morelli L, Masci G, Losurdo A, Curigliano G, Kobold S, Penna G, Rescigno M.
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by Chitinase 3-like-1.
Journal for Immunotherapy of Cancer 2021; 9:e003224.
JIF²⁰²⁰ 13.8

204. Cadilha B, Benmebarek MR, Dorman K, Oener A, Lorenzini T, Obeck H, Väntinnen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Maerkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S.
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumor.
Science Advances 2021; 7:eabi5781.
JIF²⁰²⁰ 13.1
https://pubmed.ncbi.nlm.nih.gov/34108220/

203. Winheim E, Rinke L, Lutz K, Reischer A, Leutbecher A, Wolfram L, Rausch L, Kranich J, Wratil PR, Huber JE, Baumjohann D, Rothenfusser S, Schubert B, Hilgendorff A, Hellmuth JC, Scherer C, Muenchhoff M, von Bergwelt-Baildon M, Stark K, Straub T, Brocker T, Keppler OT, Subklewe M, Krug AB.
Impaired function and delayed regeneration of dendritic cells in COVID-19.
PLOS Pathogens 2021; 17:e1009742.
JIF²⁰²⁰ 6.2
https://pubmed.ncbi.nlm.nih.gov/34614036/

203. Schneider M, Heeb L, Beffinger M, Pantelyushin S, Linecker M, Roth L, Lehmann K, Ungethüm U, Kobold S.
Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models.
Science Translational Medicine 2021; 13:eabc8188.
JIF²⁰²⁰ 16.3
https://www.science.org/doi/10.1126/scitranslmed.abc8188

203. Tokarew N, Gosalvez Suarez J, Nottebrock A, Briukhovetska D, Endres S, Cadilha B, Kobold S.
Flow cytometry detection and quantification of CAR T cells into solid tumors.
Methods in Cell Biology 2021;
JIF²⁰²⁰ 1.4
https://www.sciencedirect.com/science/article/pii/S0091679X21000583?dgcid=author

202. Boehmer D, Formisano S, de Oliveira Mann C, Mueller S, Kluge M, Metzger P, Rohlfs M, Hörth Ch, Kocheise L, Lichtenthaler S, Hopfner KP, Endres S, Rothenfusser S, Friedel C, Duewell P, Schnurr* M, Koenig* L.
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.
Science Immunology 2021; 61, eabe2550.
JIF²⁰²⁰ 30.6
https://immunology.sciencemag.org/content/6/61/eabe2550
https://www.lmu-klinikum.de/aktuelles/pressemitteilungen/programmierter-zelltod-von-tumorzellen-durch-synthetische-rna-molekule/3b1205f11defadda

201. Magg* Th, Okano* T, Koenig* L, Boehmer D, Schwartz S, Inoue K, Heimall J, Licciardi F, Ley-Zaporozhan J, Ferdman R, Park E, Calderon B, Dey D, Kanegane H, Cho K, Montin D, Reiter K, Griese M, Albert M, Rohlfs M, Gray P, Walz C, Conn G, Sullivan K, Klein Ch, Morio* T, Hauck* F.
Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency.
Science Immunology 2021; 60, eabf9564.
JIF²⁰²⁰ 30.6
https://immunology.sciencemag.org/content/6/60/eabf9564
*contributed equally

201. Di Pilato M*, Kfuri-Rubens R*, Pruessmann J*, Ozga AJ*, Messemaker M, Cadilha B, Sivakumar R, Cianciaruso Ch, Warner RD, Marangoni F, Carrizosa E, Lesch S, Billingsley J, Perez-Ramos D, Zavala F, Rheinbay E, Luster AD, Gerner MY, Kobold S, Pittet MJ, Mempel TR.
CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.
Cell 2021, 184:4512-30.
JIF²⁰²⁰ 41.6
https://www.sciencedirect.com/science/article/abs/pii/S0092867421008564?dgcid=coauthor
*contributed equally

201. Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, Dantes Z, Rataj F, Dorman K, Lutz J, Karches C, Heise C, Kurzay M, Larimer B, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth Ch, Benmebarek MR, Dhoqina D, Gruenmeier R, Seifert M, Oener A, Umut Ö, . . . Rothenfusser S, Duewell P, Koenig L, Schnurr M, Subklewe M, Liss A, Halama N, Reichert M, Mempel T, Endres S, Kobold S.
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
Nature Biomedical Engineering 2021; 35:2243-2257.
JIF²⁰²⁰ 20.0
https://www.nature.com/articles/s41551-021-00737-6
https://www.lmu-klinikum.de/aktuelles/pressemitteilungen/neue-strategie-gegen-bauchspeicheldrusenkrebs/f95d2c0d7ad55197

200. Linder A, Bothe V, Linder N, Schwarzlmüller P, Dahlström F, Bartenhagen Ch, Dugas M, Pandey D, Thorn-Seshold J, Boehmer D, König LM, Kobold S, Schnurr M, Rädler J, Spielmann G, Karimzadeh H, Schmidt A, Endres S, Rothenfusser S.
Defective interfering genomes and the full-length viral genome trigger RIG-I after infection with vesicular stomatitis virus in a replication dependent manner.
Frontiers in Immunology 2021; 12:595390.
JIF²⁰²⁰ 6.4
http://journal.frontiersin.org/article/10.3389/fimmu.2021.595390/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Immunology&id=595390

199. Blaeschke F, Stenger D, Apfelbeck A, Cadilha B, Benmebarek MR, Mahdawi J, Ortner E, Lepenies M, Habjan N, Rataj F, Willer S, Kaeuferle T, Majzner R, Busch D, Kobold S, Feuchtinger T.
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.
Blood Cancer Journal 2021; 11:108.
JIF²⁰²⁰ 8.0

199. Brand I, Gilberg L, Bruger JM, Gari M, Wieser A, Eser TM, Frese J, Ahmed M, Rubio-Acero R, Guggenbuehl Noller JM, Casteletti N, Diekmannshemke J, Thiesbrummel S, Huynh D, Winter S, Fuchs Ch, Hoelscher M, Roider J, Kobold S, Pritsch M, Geldmacher Ch.
Broad T cell targeting of structural proteins after SARS-CoV-2 infection: High throughput assessment of T cell reactivity using an automated interferon gamma release assay.
Frontiers in Immunology 2021; 12:688436.
JIF²⁰²⁰ 6.4

199. Sams L, Kruger S, Heinemann V, Bararia D, Haebe S, Alig S, Haas M, Zhang D, Westphalen CB, Ormanns S, Metzger P, Werner J, Weigert O, von Bergwelt‐Baildon M, Rataj F, Kobold S, Boeck S.
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab‐paclitaxel.
Clinical and Translational Oncology 2021; 23:2394-2401.
JIF²⁰²⁰ 2.8

199. Karaki S, Blanc C, Tran T, Galy-Fauroux I, Mougel A, Dransart E, Anson M, Tanchot C, Paolini L, Gruel N, Gibault L, Le Pimpec-Barthes F, Fabre E, Benhamouda N, Badoual C, Damotte D, Donnadieu E, Kobold S, Mami-Chouaib F, Golub R, Johannes L, Tartour E.
CXCR6-deficiency impairs cancer vaccine efficacy and CD8+resident memory T cell recruitment in head and neck and lung tumors.
Journal for Immunotherapy for Cancer 2021; 9:e001948.
JIF²⁰²⁰ 10.3
https://cancerimmunolres.aacrjournals.org/content/7/2_Supplement/A172

199. Benmebarek MR, Cadilha B, Hermman M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger Ch, Brauchle B, Rohrbacher L, Oener A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein Ch, Subklewe M, Endres S, Hopfner KP, Kobold S.
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Leukemia 2021; 35:2243-2257.
JIF²⁰²⁰ 8.7
https://pubmed.ncbi.nlm.nih.gov/33414484/

198. Kuhlmann C, Schenck TL, Tluczynski K, Aszodi A, Metzger P, Giunta R, Wiggenhauser PS.
Experimental approach to nasal septal cartilage regeneration with adipose tissue-derived stem cells and decellularized porcine septal cartilage.
Xenotransplantation 2020; 1-11.
JIF²⁰¹⁹ 3.5
https://pubmed.ncbi.nlm.nih.gov/33350016/

198. Piseddu I, Röhrle N, Knott M, Moder S, Eiber S, Schnell K, Vetter V, Meyer B, Layritz P, Kühnemuth B, Wiedemann G, Grün J, Perleberg C, Rapp M, Endres S, Anz D.
Constitutive expression of CCL22 Is mediated by T cell-derived GM-CSF.
The Journal of Immunology 2020; 205:2056-2065.
JIF²⁰¹⁹ 4.3
https://pubmed.ncbi.nlm.nih.gov/32907996/

197. Segura-Bayona S, Villamor-Paya M, Attolini C, Koenig LM, Sanchiz-Calvo M, Boulton SJ, Stracker TH.
Tousled-like kinases suppress innate immune signaling triggered by alternative lengthening of telomeres.
Cell Reports 2020; 32:107983.
JIF²⁰¹⁹ 7.7
https://pubmed.ncbi.nlm.nih.gov/32755577/

197. Boehmer D, Koehler L, Magg T, Metzger P, Rohlfs M, Ahlfeld J, Rack-Hoch A, Reiter K, Albert M, Endres S, Rothenfusser S, Klein Ch, Koenig L, Hauck F.
A novel complete autosomal recessive STAT1 LOF variant causes immunodeficiency with hemophagocytic lymphohistiocytosis-like hyperinflammation.
The Journal of Allergy and Clinical Immunology 2020; 8:3102-3111.
JIF²⁰¹⁹ 10.3
https://pubmed.ncbi.nlm.nih.gov/32603902/

196. Geiger M, Stubenrauch KG, Sam J, Richter W, Jordan G, Eckmann J, Hage C, Gonzalez-Nicolini V,
Freimoser-Grundschober A, Ritter M, Lauer M, Stahlberg H, Ringler P, Patel J, Sullivan E, Grau-Richards S, Endres S, Kobold S, Umaña P, Brünker P, Klein Ch.
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
Nature Communications 2020; 11:3196. Featured in Editors‘ Highlights “Translational and clinical research”
JIF²⁰¹⁹ 12.1
https://pubmed.ncbi.nlm.nih.gov/32581215/ 

195. Metzger P, Kirchleitner S, Boehmer D, Hörth Ch, Eisele A, Ormanns S, Gunzer M, Lech M, Lauber K, Endres S, Duewell P, Schnurr M, König L.
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Cancer Immunology, Immunotherapy 2020; 69:2101-2112.
JIF²⁰¹⁹ 4.9
https://pubmed.ncbi.nlm.nih.gov/32448983/

195. Stenger D, Stief T, Kaeuferle T, Willier S, Rataj F, Schober K, Binje V, Lotfi R, Wagner B, Grünewald T, Kobold S, Busch D, Jeremias I, Blaeschka F, Feuchtinger T.
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Blood 2020; 136:1407-1418.
JIF²⁰¹⁹ 10.7
https://pubmed.ncbi.nlm.nih.gov/32483603/

195. Huber J*, Ahlfeld J*, Scheck M, Zaucha M, Witter K, Lehmann L, Karimzadeh H, Pritsch M, Hölscher M, von Sonnenburg F, Dick A, Barba-Spaeth G, Krug A, Rothenfußer S*, Baumjohann D* .
Dynamic changes in circulating T follicular helper cell composition predict neutralizing antibody responses after yellow fever vaccination.
Clinical & Translational Immunology 2020; 9:e1129.
* equally contributed
JIF²⁰¹⁹ 6.5
https://pubmed.ncbi.nlm.nih.gov/32419947/

193. Metzger P, Kirchleitner S, Kluge M, Koenig L, Hoerth Ch, Rambuscheck CA, Boehmer D, Ahlfeld J, Kobold S, Friedel C, Endres S, Schnurr M, Duewell P.
Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.
Journal for Immunotherapy of Cancer 2019; 7:288.
JIF²⁰¹⁹ 8.7
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836385/

193. Scherm M, Serr I, Zahm A, Schug J, Bellusci S, Manfredini R,Salb V, Gerlach K, Weigmann B, Ziegler AG, Kästner KH, Daniel C.
miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes.
Nature Communications 2019; 10:5697.
JIF²⁰¹⁹ 12.1

193. Scherm M, Serr I, Kästner KH, Daniel C.
The role of T cell miRNAs for regulatory T cell induction in islet autoimmunity.
Molecular Metabolism 2019; 27S:S122-S128.
JIF²⁰¹⁹ 6.5

193. Becker M, Serr I, Salb V, Ott V, Mengel L, Blüher M, Weigmann B, Hauner H, Tschöp M, Daniel C.
Short-term cold exposure supports human Treg induction in vivo.
Molecular Metabolism 2019; 28:73-82.
JIF²⁰¹⁹ 6.5

193. Lorenz G, Moschovaki-Filippidou F, Würf V, Metzger P, Steiger S, Batz F, Carbajo-Lozoya J, Koziel J, Schnurr M, Cohen CD, Schmaderer Ch, Anders HJ, Lindenmeyer M, Lech M*.
IFN regulatory factor 4 controls post-ischemic inflammation and prevents chronic kidney disease.
Frontiers in Immunology 2019; 10:2162.
JIF²⁰¹⁹ 5.1

192. Schewe J, Makeschin MC, Liss I, Mayr D, Zhang J, Khandoga A, Rothenfußer S, Schnurr M, Gerbes AL, Steib CJ.
Ischemic postconditioning (IPostC) protects fibrotic and cirrhotic rat livers after warm ischemia.
Canadian Journal of Gastroenterology and Hepatology 2019; 2019:5683479.
JIF²⁰¹⁹ 2.1

192. Helms M, Jahn-Hofmann K, Gnerlich F, Metz-Weidmann Ch, Braun M, Dietert G, Scherer P, Grandien K, Theilhaber J, Cao H, Wagenaar T, Schnurr M, Endres S, Wiederschain D, Scheidler S, Rothenfusser S, Brunner B, Koenig L.
Utility of the RIG-I agonist triphosphate RNA for melanoma therapy.
Molecular Cancer Therapeutics 2019; 18:2343-2356.
JIF²⁰¹⁹ 5.6
https://www.ncbi.nlm.nih.gov/pubmed/31515294

191. Mountford SA, Ringleb A, Schwaiger R, Mayr D, Kobold S, Dinarello Ch, Bufler P.
Interleukin-37 inhibits colon carcinogenesis during chronic colitis.
Frontiers in Immunology 2019; 10:2632.
JIF²⁰¹⁹ 5.1

191. Brown P, Tan AC, El-Esawi MA, Liehr T, Blanck O, Gladue DP, ...Kobold S, ..., Veys R, Zhou YQ.
Large expert-curated database for benchmarking document similarity detection in biomedical literature search.
Database 2019; doi: 10.1093.
JIF²⁰¹⁹ 2.6

191. Küpper C, Heinrich J, Kamm K, Bücklein V, Rothenfusser S, Straube A.
Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency.
Neurology Neuroimmunology & Neuroinflammation 2019; 6:e628.
JIF²⁰¹⁹ 7.7 

191. Darowski D, Jost Ch, Stubenrauch K, Wessels U, Benz J, Ehler A, Freimoser-Grundschober A, Brünker P, Mössner E, Umana P, Kobold S, Klein Ch.
P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.
Protein Engineering, Design and Selection 2019; 32:207-218.
JIF²⁰¹⁹ 1.9

191. Wiedemann G, Röhrle N, Makeschin MC, Fesseler J, Endres S, Mayer D, Anz D.
Peritumoral CCL1 and CCL2 expressing cells in hepatocellular carcinomas shape the tumor immune infiltrate.
Pathology 2019; 51:586-592.
JIF²⁰¹⁹ 3.8
https://www.ncbi.nlm.nih.gov/pubmed/31445808

190. Karches C, Benmebarek MR, Schmidbauer M, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha B, Lesch S, Heise C, Murr R, vom Berg J, Jastroch M, Lamp D, Ding J, Duewell P, Niederfellner G, Sustmann C, Endres S, Klein Ch, Kobold S.
Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy.
Clinical Cancer Research 2019; 25:5890-5900.
JIF²⁰¹⁹ 10.1
https://www.ncbi.nlm.nih.gov/pubmed/31285373

189. Rapp M, Wintergerst M, Kunz W, Vetter V, Knott M, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian U, Endres S*, Anz D. (*corresponding author)
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
Journal of Experimental Medicine 2019; 116:5514-5522.
JIF²⁰¹⁹ 11.7
https://www.ncbi.nlm.nih.gov/pubmed/3091079  

188. Liu X, Li J, Cadilha B, Markota A, Voigt C, Huang Z, Lin P, Wang D, Juncheng D, Kranz G, Krandick A, Libl D, Zitzelsberger H, Zagorski I, Braselmann H, Pan M, Zhu S, Huang Y, Niedermeyer S, Reichel Ch, Uhl B, Briukhovetska D, Suarez Gosalvez J, Kobold S, Gires O, Wang H.
Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis.
Science Advances 2019; 5:eaav4275.
JIF²⁰¹⁹ 13.1  

188. Eisenmesser EZ, Gottschlich A, Redzic JS, Paukovich N, Nix JC, Azam T, Zhang L, Zhao R, Kieft JS, The E, Meng X, Dinarello CA.
Interleukin-37 monomer is the active form for reducing innate immunity.
Proceedings of the National Academy of Sciences 2019; 116:5514-5522.
JIF²⁰¹⁹ 9.4
https://www.ncbi.nlm.nih.gov/pubmed/30429531

188. Rataj F, Jacobi S, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha B, van Puijenbroek E, Heise C, Duewell P, Endres S, Klein Ch, Kobold S.
High affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
British Journal of Cancer 2019; 120:79-87.
JIF²⁰¹⁹ 5.8
https://www.ncbi.nlm.nih.gov/pubmed/30429531

187. Wiedemann G, Aithal C, Kraechan A, Heise C, Cadilha B, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold S.
Microphthalmia-associated transcription factor (MITF) regulates immune cell migration into melanoma.
Translational Oncology 2019; 12:350-360.
JIF²⁰¹⁹ 3.6

186. Karsten MM, Enders S, Knabl J, Kirn V, Duewell P, Rack B, Blohmer JU, Mayr D, Dian D.
Biologic meshes and synthetic meshes in cancer patients: a double-edged sword: differences in production of IL-6 and IL-12 caused by acellular dermal matrices in human immune cells.

Archives Gynecology Obstetrics 2018; 297:1265-1270.
JIF²⁰¹⁸ 2.2

186. Kuehnemuth B, Piseddu I, Wiedemann G, Lauseker M, Kuhn Ch, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D.
CCL1 is a major regulatory T cell attracting factor in human breast cancer.
BMC Cancer 2018; 18:1278.

JIF²⁰¹⁸ 2.9

185. Weidenbusch M, Song S, Iwakura T, Shi C, Rodler S, Kobold S, Mulay SR, Honarpisheh MM, Anders HJ.
IL-22 sustains epithelial integrity in progressive kidney remodeling and fibrosis.
Physiological Reports 2018; 6:e13817.
JIF²⁰¹⁸ 1.3

185. Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Blood 2018; 32:2484-2494.
JIF²⁰¹⁸ 15.1

185. Rataj F, Kraus F, Chaloupka M, Grassmann S, Heise C, Cadilha B, Duewell P, Endres S, Kobold S.
PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin-lymphoma.

Frontiers in Immunology 2018; 9:1955.

JIF²⁰¹⁸ 4.7
https://www.frontiersin.org/articles/10.3389/fimmu.2018.01955/full

184. Metzger P, Kirchleitner S, König L, Hörth Ch, Kobold S, Endres S, Schnurr M, Duewell P.
Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.
Science Reports 2018; 8:8810.
JIF²⁰¹⁸ 4.1 

183. Andrade L, Tay R, Pan D, Luoma A, Ito Y, Badrinath S, Tsoucas D, Franz B, May K, Harvey Ch, Kobold S, Pyrdol J, Yoon Ch, Yuan G, Hodi S, Dranoff G, Wucherpfennig K.
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity.
Science 2018; 359:1537-1542.

JIF²⁰¹⁸ 41.1
https://www.ncbi.nlm.nih.gov/pubmed/29599246

183. Makanyengo R, Duewell P, Reichl C, Hörth Ch, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold S, Endres S, Schnurr M, Bauer Ch.
Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gut.
JCI Insight 2018; 8;3(5).

JIF²⁰¹⁸ 6,0

182. Christ A, Günther P, Lauterbach MAR, Duewell P, Biswas D, Pelka K, Scholz CJ, Oosting M, Haendler K, Baßler K, Klee K, Schulte-Schrepping J, Ulas T, Moorlag SJCFM, Kumar V, Park MH, Joosten LAB, Groh LA, Riksen NP, Espevik T, Schlitzer A, Li Y, Fitzgerald ML, Netea MG, Schultze JL, Latz E.
Western diet triggers NLRP3-dependent innate immune reprogramming.
Cell 2018; 172:162-175.
JIF²⁰¹⁸ 31.4
https://www.ncbi.nlm.nih.gov/pubmed/29328911

182. Damby D, Horwell C, Baxter P, Kueppers U, Schnurr M, Dingwell D, Duewell P.

Volcanic ash activates the NLRP3 inflammasome in murine and human macrophages.
Frontiers in Immunology 2017; 8:2000.
JIF²⁰¹⁸ 6.4
https://www.ncbi.nlm.nih.gov/pubmed/29403480

182. Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt K, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler W, Schnurr M, Rothenfußer S, Endres S, Kobold S.
Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.
Proceedings of the National Academy of Sciences 2017; 10:1073.
JIF 9.6
https://www.ncbi.nlm.nih.gov/pubmed/?term=voigt+c+may+p
* contributed equally to this study

181. Zwicker S, Hattinger E, Bureik D, Batycka-Baran A, Schmidt A, Gerber PA, Rothenfusser S, Gilliet M, Ruzicka T, Wolf R.
Th17 micro-milieu regulates NLPR1-dependent caspase-5 activity in skin autoinflammation.
PLoS One 2017; 12:e0175153.
JIF 3.5

181. Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H.
Data on chow, liver tissue and mitochondrial fatty acid compositions as well as mitochondrial proteome changes after feeding mice a western diet for 6-24 weeks.
Data Brief 2017; 15:163-169.

181. Ahlfeld J, Filser S, Schmidt F, Wefers AK, Merk DJ, Glaß R, Herms J, Schüller U
Neurogenesis from Sox2 expressing cells in the adult cerebellar cortex.
Scientific Report - Nature 2017; 7:6137.
JIF 4.3

181. Freier CP, Kuhn C, Endres S, Mayr D, Freise K, Jeschke U, Anz D.
FOXP3+ cells recruited by CCL22 into breast cancer correlates with less tumor nodal infiltration.
Anticancer Research 2016; 36:3139-45.
JIF 1.9

180. Matheis F, Heppt MV, Graf SA, Düwell P, Kammerbauer C, Aigner A, Besch R, Berking C.
A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma.
Journal of Investigative Dermatology 2016, 136:2475-2484.
JIF 6,3

180. Tufman A, Huber RM, Völk S, Aigner F, Edelmann M, Gamarra F, Kiefl R, Kahnert K, Tian F, Boulesteix AL, Endres S, Kobold S.

Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases.
BMC Cancer 2016; 16:409.
JIF 3.8

179. Wiedemann G, Jacobi S, Chaloupka M, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S.

A novel TLR7 agonist reverses NK cell anergy and cures lymphoma-bearing mice.
Oncoimmunology 2016; 5:e1189051.

JIF 6.3  

178. Wiedemann G, Knott M, Vetter V, Rapp M, Haubner S, Fesseler J, Kühnemuth B, Layritz P,
Thaler R, Kruger S, Ormanns S, Mayr D, Endres S, Anz D.
Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells.
Oncoimmunology 2016; 5:e1175794.
JIF 6.3

177. Hotz C, Treinis M, Mottas I, Rötzer L, Oberson A, Spagnuolo L, Perdicchio M, Spinetti T, Herbst T, Bourquin C.
Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.
Oncoimmunology 2016; 5:e1232219.
JIF 7.7

177. Roskopf CC, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, Oduncu FS.
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.
Oncotarget 2016; 7:22579-89.
JIF 6.6

177. Pritsch M, Ben-Khaled N, Chaloupka M, Kobold S, Berens-Riha N, Peter A, Liegl G, Schubert S, Hölscher M, Löscher T, Wieser A.
Comparison of intranasal outer membrane vesicles with cholera toxin and injected MF59C.1 as adjuvants for malaria transmission blocking antigens AnAPN1 and Pfs48/45.
Journal of Immunology Research 2016; 2016:3576028.
JIF 2.9

177. Castoldi R, Schanzer J, Panke C, Jucknischke U, Neubert N, Croasdale R, Klein C,
Scheuer W, Niederfellner G, Auer J, Kobold S, Sustmann C.
TetraMabs: Simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.
Protein Engineering Design and Selection 2016; 29:467-75.
JIF 2.5

176. Heidegger S, Jarosch A, Schmickl M, Endres S, Bourquin C, Hotz C.
Mycoplasma hyorhinis-contaminated cell lines activate primary innate immune cells via a protease-sensitive factor.
PLOS ONE 2015; 10:e0142523.
JIF 3.7

175. Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S.
C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.

Oncoimmunology 2015; 5:e1105428.
JIF 6.3

174. Lichtenegger F, Kondla I, Krempasky M, Weber A, Herold T, Krupka C, Spiekermann K.
RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
Cancer Immunology Immunotherapy 2015; 64:1505-15.
JIF 4.0

174. Anz D, Rapp M, Eiber S, Koelzer V, Thaler R, Haubner S, Knott M, Nagel S, Golic M, Wiedemann G, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S, Bourquin C.
Suppression of intratumoral CCL22 by type I interferon inhibits migration of regulatory T cells and blocks cancer progression.
Cancer Research 2015; 75:4483-93.
JIF 9.3

173. Häcker G, Senft D, Weber A, Saathoff F, Berking C, Heppt M, Kammerbauer C, Rothenfusser S, Kellner S, Kurgys Z, Besch R.
In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins.

Cell Death and Disease 2015; 6:e1996.
JIF 5.0

173. Hotz C, Roetzer L, Huber T, Sailer A, Oberson A, Treinies M, Heidegger S, Herbst T, Endres S, Bourquin C.
TLR and RLR signaling are reprogrammed in opposite directions after detection of viral infection.
The Journal of Immunology 2015; 195:4387-95.
JIF 5.4

172. Schnarfell F, Lichtenegger F, Emmerig K, Schlueter M, Neitz J, Draenert R, Hiddemann W, Subklewe M.
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.

Journal of Haematology and Oncology 2015; 8:93.
JIF 4.9

172. Kobold* S, Grassmann* S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, Endres S#, Rothenfußer S#.

Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy.
The Journal of the National Cancer Institute 2015; 107.
* contributed equally to this study, # share senior authorship
JIF 15.2
http://www.ncbi.nlm.nih.gov/pubmed/26105028

171. Freier C, Kuhn C, Rapp M, Endres S, Mayr D, Friese K, Anz D, Jeschke U.
Expression of CCL22 and infiltration by regulatory T-cells are increased in the decidua of human miscarriage placentas.
American Journal of Reproductive Immunology 2015; 74:216-27.
JIF 2.7

170. Duewell P, Beller E, Kirchleitner S, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold S, Endres S, Schnurr M.
Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.
OncoImmunology 2015; 4:e1029698.
JIF 6.3

169. Bauer C, Hees C, Sterzik A, Bauernfeind F, Mak´Anyengo R, Duewell P, Lehr HA, Noessner E, Wank R, Trauzold A, Endres S, Dauer M, Schnurr M.

Pro- and anti-apoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells towards gemcitabine and T cell-mediated cytotoxicity.
Journal of Immunotherapy 2015; 38:116-26.
JIF 3.4

168. Kocabey S, Meinl H, MacPherson IS, Cassinelli V, Manetto A, Rothenfusser S, Liedl T, Lichtenegger FS.
Cellular uptake of Tile-assembled DNA nanotubes.
Journal of Nanomaterials 2015; 47-60.
JIF 2.4

167. Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger J, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner CG, Klein C, Bourquin C, Endres S.
Selective bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer.

The Journal of the National Cancer Institute 2014; 107:364.
JIF 15.2

166. Duewell P, Steger A, Lohr H, Bourhis H, Hoelz H, Kirchleitner SV, Stieg MR, Grassmann S, Kobold S, Siveke JT, Endres S, Schnurr M.

RIG-I-like helicases induce immunogenic cell death of pancreatic cancer and sensitize tumors killing by CD8+ T-cells.
Cell Death and Differentiation 2014; 21:1825-37.
JIF 8.4

165. Hermans C, Anz D, Engel J, Kirchner T, Endres S, Mayr D.
Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.
PLOS One 2014; 9:e111757
JIF 2.8  

165. Roskopf CC, Schiller C, Braciak TA, Kobold S, Schubert A, Fey GH, Hopfner KP, Oduncu F.
T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell.
Oncotarget 2014; 5:6466-83.
JIF 6.6

165. Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D.
Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.

Cancer Immunology Immunotherapy 2014; 63:1151-62.
JIF 3.6

165. Wilson NS, Duewell P, Yang B, Li Y, Marsters S, Koernig S, Latz E, Maraskovsky E, Morelli AB, Schnurr M, Ashkenazi A.
Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant.
The Journal of Immunology 2014; 192:3259-68.
JIF 5.5

165. Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Blood 2014; 123:356-65.
JIF 9.9

165. Bauer C, Sterzik A, Bauernfeind F, Duewell P, Conrad C, Kiefl R, Endres S, Eigler A, Schnurr M, Dauer M.
Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in an murine pancreatic carcinoma model.
Cancer Immunology Immuntherapy 2014; 63:321-33.
JIF 3.6

164. Kim S, Kaiser V, Beier E, Bechheim M, Guenthner-Biller M, Ablasser A, Berger M, Endres S, Hartmann G, Hornung V.
Self-priming determines high type I IFN production by plasmacytoid dendritic cells.
European Journal of Immunology 2014; 44:807-18.
JIF 5.0

163. Kulkarni P. O*, Hartter I*, Mulay R. S*, Hagemann J, Darisipudi N. M, Kumar S, Romoli S, Thomasova D, Ryu M, Kobold S, Anders HJ.
TLR4-induced IL-22 release accelerates kidney regeneration.
Journal of the American Society of Nephrology 2014; 25:978-89.
JIF 9.0 *diese Autoren leisteten gleichwertigen Beitrag

163. Anz D, Kruger S, Haubner S, Rapp M, Bourquin C, Endres S.
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses.
Diabetes, Obesity and Metabolism 2014; 16:569-72.
JIF 5.2

161. Heidegger S*, Anz D*, Stephan N, Bohn B, Herbst T, Fendler WP, Suhartha N, Sandholzer N, Kobold S, Hotz C, Eisenaecher K, Radtke-Schuller S, Endres S, Bourquin C.
Virus-associated activation of innate immunity induces rapid disruption of Peyer’s patches in mice.
Blood 2013; 122:2591-9.
JIF 9.1 *diese Autoren leisteten gleichwertigen Beitrag

160. Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufmann A, Düwell P, Lindner M, Koch I, Heidegger S, Merk M, Rothenfußer S, Schnurr M, Huber RM, Sauter G, Wilczak W, Endres S.

Interleukin-22 is frequently in lung cancer and may contribute to tumor progression in chemotherapy-resistant disease.

Journal of Thoracic Oncology 2013; 8:1032-1042.
JIF 4.5

159. Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C.

A novel bispecific EGFR/Met antibody blocks tumor promoting phenotypic effects induced by resistance to EGFR inhibition and has potent anti-tumor activity.

Oncogene 2013; 32:5593-601.
JIF 7.4

159. Hohenauer T, Berking C, Schmidt A, Haferkamp S, Senft D, Kammerbauer C, Fraschka S, Graf SA, Irmler M, Beckers J, Flaig M, Aigner A, Höbel S, Hoffmann F, Hermeking H, Rothenfusser S, Endres S, Ruzicka T, Besch R.
The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival.

EMBO Molecular Medicine 2013; 5:919-34.

JIF 7.8

158. Heidegger S, Kirchner SK, Stephan N, Bohn B, Suhartha N, Hotz C, Anz D, Sandholzer N, Stecher B, Rüssmann H, Endres S, Bourquin C.
TLR activation excludes circulating naive CD8+ T cells from gut-associated lymphoid organs in mice.
Journal of Immunology 2013; 190:5313-20.
JIF 5.5

157. Schmidt K, Zilio S, Schmollinger JC, Bronte V, Blankenstein T, Willimsky G.
Differently immunogenic cancers in mice induce immature myeloid cells that suppress.
CTL in vitro but not in vivo following transfer.
Blood 2013; 121:1740-8.
JIF 9.1

157. Ellermeier J, Wei J, Düwell P, Hoves S, Stieg M, Adunka T, Nörenberg D, Anders HJ, Mayr D,
Pöck H, Hartmann G, Endres S, Schnurr M.
Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Cancer Research 2013; 73:1709-20.
JIF 8.7

155. Merk M, Mitchell R, Endres S, Bucala R.
D-dopachrome tautomerase (D-DT or MIF-2): Doubling the MIF cytokine family.
Cytokine 2012; 59:10-7.
JIF 3.5

154. Kobold S, Luetkens T, Bartels BM, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D.
Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
Clinical and Developmental Immunology 2012; 2012:134081.
JIF 1.8

154. Vollbrecht T, Stirner R, Tufman A, Roider J, Huber RM, Bogner JR, Lechner A, Bourquin C,
Draenert R. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells.

AIDS 2012; 26:F31-7.
JIF 6.4

154. Bauer C, Duewell P, Lehr HA, Endres S, Schnurr M.

Protective and aggravating effects of Nlrp3 inflammasome activation in IBD Models: influence of genetic and environmental factors.
Digestive Diseases 2012; 1:82-90.
JIF 2.7

153. Wenzel M, Wunderlich M, Besch R, Poeck H, Willms S, Schwantes A, Kremer M, Sutter G, Endres S, Schmidt A, Rothenfusser S.
Cytosolic DNA triggers mitochondrial apoptosis via DNA-damage signalling proteins independently of AIM2 and RNA polymerase III.
Journal of Immunology 2012; 188:394-403.
JIF 5.5

151. Schueller V, Heidegger S, Sandholzer N, Suhartha N, Nickels P, Endres S, Bourquin C, Liedl T.
Cellular immunostimulation by CpG-sequence-coated DNA origami structures.
American Chemical Society ACS Nano 2011; 5:9696-702.
JIF 12.1

150. Kobold S, Isernhagen J, Hübel K, Kilic N, Bogner C, Frickhofen N, Bokemeyer C, Fiedler W.
Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.
Bone Marrow Transplantation 2011; 46:1053-6.
JIF 3.5

150. Lech M, Kantner C, Kulkarni O, Ryu M, Vlasova E, Heesemann J, Anz D, Endres S, Martin J, Koichi S, Kobayashi K, Flavell RA, Anders HJ.
Interleukin-1 receptor-associated kinase-M suppresses systemic lupus erythematosus.
Annals of the Rheumatic Diseases 2011; 70:2207-17.
JIF 9.1

149. Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, Fan J, Lue H, Chen Y, Xiong H, Chagnon F, Bernhagen J, Lolis E, Mor G, Lesur O, Bucala R.
The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF).
Proceedings of the National Academy of Sciences USA 2011; 108:E577-85.
JIF 9.7

149. Anz D, Eiber S, Scholz C, Endres S, Kirchner T, Bourquin C, Mayr D.

In breast cancer a high ratio of tumor-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype.
Histopathology 2011; 59:965-74.
JIF 2.9

148. Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D.

Patients with multiple myeloma develop SOX2-Specific autoantibodies after allogeneic stem cell transplantation.

Clinical and Developmental Immunology 2011; 2011:302145.

JIF 3.1

148. Bourquin C, Hotz C, Noerenberg D, Völkl A, Heidegger S, Storch B, Sandholzer N,
Wurzenberger C, Anz D, Endres S.
Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance.
Cancer Research 2011; 71:5123-33.
JIF 8.7

147. Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Morelli AB, Koernig S, Clausen BE, Dauer M, Eigler A, Anz D, Bourquin C, Maraskovsky E, Endres S, Schnurr M.

ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Journal of Immunology 2011; 187:55-63.
JIF 5.5

146. Bauer C, Dauer M, Saraj S, Bauernfeind F, Sterzik A, Junkmann J, Jakl V, Kiefl R, Schnurr M, Oduncu F, Emmerich B, Mussack T, Bruns C, Rüttinger D, Conrad C, Jauch KW, Endres S, Eigler A.

Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study.
Cancer Immunology Immunotherapy 2011; 60:1097-107.
JIF 3.6

145. Zoglmeier C, Bauer H, Noerenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C.
CpG blocks immune suppression by myeloid-derived suppressor cells in tumor-bearing mice. (see editorial: Lechner M, Epstein A. A new mechanism for blocking myeloid-derived suppressor cells by CpG. Clin Canc Res 2011 Feb.)
Clinical Cancer Research 2011; 17:1765-75.
JIF 7.8

144. Anz D, Mueller W, Golic M, Kunz WG, Rapp M, Koelzer VH, Ellermeier J, Ellwart JW, Schnurr M, Bourquin C, Endres S.

CD103 is a hallmark of tumor-infiltrating regulatory T cells.

International Journal of Cancer 2011;129:2417-26.
JIF 6.2

142. Bourquin C, Wurzenberger C, Heidegger S, Fuchs S, Anz D, Weigel S, Sandholzer N, Winter G, Coester C, Endres S.
Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response.
Journal of Immunotherapy 2010; 339:935-44.
JIF 3.5

141. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E.
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Nature 2010; 464:1357-6.

JIF 38.6

141. Bourquin C, von der Borch P, Zoglmeier C, Anz D, Sandholzer N, Wurzenberger C, Denzel A, Kammerer R, Zimmermann R, Endres S.
Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in a SV40 T antigen mouse model.
Journal of Immunology 2010; 185:2580-8.
JIF 5.5

140. Bauer C, Duewell P, Mayer T, Lehr HA, Fitzgerald KA, Tschopp J, Endres S, Latz E, Schnurr M.
Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NALP3 inflammasome.
Gut 2010; 59:1192-9.
JIF 10.7

138. Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hannesschläger N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, Hartmann G, Hornung V, Ruland J.
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin-1β production.
Nature Immunology 2009; 11:63-9.
JIF 26.2

137. Berchthold C, Panthel K, Jellbauer S, Köhn B, Roider E, Partilla M, Heesemann J, Endres S, Bourquin C, Rüssmann H.
Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant salmonella.
Infection and Immunity 2009; 77:5501-5508.
JIF 4.1

136. Bourquin C, Schmidt L, Lanz AL, Storch B, Wurzenberger C, Anz D, Berger M, Poeck H, Hartmann G, Hornung V, Endres S.
Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through TLR7.
Journal of Immunology 2009; 183:6078-86.
JIF 5.5

135. Berger M, Ablasser A, Kim S, Bekeredjian-Ding I, Giese T, Endres S, Hornung V, Hartmann G.
TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA.
Journal of Immunotherapy 2009; 32:262-71.
JIF 3.5

134. Schmidt A, Schwerd T, Hellmuth J, Sheng C, Wenzel M, Hoffmann F, Poeck H, Michallet MC, Besch R, Hopfner KP, Endres S, Rothenfusser S.
5'-triphosphate RNA requires base-paired structures to activate anti-viral signaling via RIG-I.
Proceedings of the National Academy of Sciences USA 2009; 106:12067-72.
JIF 9.7

133. Besch R, Poeck H, Hohenauer T, Senft D, Haecker G, Berking C, Hornung V, Endres S, Ruzicka T, Rothenfusser S, Hartmann G.
Proapoptotic signalling by RIG-I and MDA-5 results in tumorspecific apoptosis independent of type I interferons in melanoma.
Journal of Clinical Investigation 2009; 119:2399-411.
JIF 12.8

132. Ablasser A, Poeck H, Berger M , Schlee M, Kim S, Bourquin C, Goutagny N, Jiang Z, Fitzgerald KA, Anz D, Rothenfusser S , Endres S , Hartmann G, Hornung V.
Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes.
Journal of Immunology 2009; 182:6824-33.
JIF 5.5

131. Bekeredjian-Ding I, Schaefer M, Hartmann E, Pies R, Parcina M, Schneider P, Giese T, Endres S, Wollenberg B, Hartmann G.
Tumour-derived prostaglandin E2 and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α.
Immunology 2009; 128:439-450.
JIF 3.7

130. Haasters F, Prall WC, Anz D, Endres S, Mutschler M, Dochenva D, Schieker M.
Morphological and immunological characteristics indicate the yield of early progenitors and represent a quality control for human mesenchymal stem cell culturing.
Journal of Anatomy 2009; 214:759-767.
JIF 2.4

129. Gross O, Poeck H, Bscheider M, Dostert C,Hannesschlaeger N, Endres S, Tardivel A, Tschopp J, Ruland J.
Syk kinase siganling couples to the Nalp3 inflammasome for anti-fungal host defense.
Nature 2009; 459:433-6.
JIF 38.6

128. Anz D, Thaler R, Stephan N,Waibler Z, Trauscheid MJ, Scholz C,Kalinke U, Barchet W, Endres S, Bourquin C.
Activation of melanoma differentiation-associated gene 5 (MDA5) and Toll-like receptors causes rapid involution of thymus.
Journal of Immunology 2009; 182:6044-50.
JIF 5.5

127. Wurzenberger C, Kölzer HV, Schreiber S, Anz D, Vollmar AM, Schnurr M, Endres S, Bourquin C.
Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo.
Cancer Immunology Immunotherapy 2009; 58:901-13.
JIF 3.6